Posted by Michael Wonder on 28 Apr 2020
FDA approves Merck’s Keytruda (pembrolizumab) for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications
28 April 2020 - Merck today announced that the U.S. FDA has approved an additional recommended dosage of 400 mg every six weeks for Keytruda, Merck’s anti-PD-1 therapy, across all adult indications, including monotherapy and combination therapy.
This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.
This new dosage option will be available in addition to the current dose of 200 mg every three weeks.
